NOT-CA-20-094: Notice of Change to Application Types Allowed in Funding Opportunity Announcement PAR-19-361 "Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)"

Notice of Change to Application Types Allowed in Funding Opportunity Announcement PAR-19-361 "Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)"

Notice Number:

NOT-CA-20-094

Key Dates

Release Date:

July 28, 2020

Related Announcements

PAR-19-361 - Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to change the Application Types Allowed in PAR-19-361 "Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)".

The following section has been amended in Part 2. Full Text of Announcement, Section II. Award Information, Application Types Allowed:

Currently reads:

New
Renewal of applications submitted to PAR-16-049
Resubmission
Revision

Has been amended to read (in italics):

New
Renewal of applications submitted to PAR-16-049 and PAR-16-051
Resubmission
Revision

All other aspects of PAR-19-361 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

(For applications that relate to therapy and resistance)

Suzanne Forry, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5922
Email: [email protected]

(For applications that relate to biology)

Ron Johnson, Ph.D.
National Cancer Institute (NCI))
Telephone: 240-276-6250
Email: [email protected]

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected].

Financial/Grants Management Contact(s)

Tawana McKeither
National Cancer Institute (NCI)
Telephone: 240-276-5217
Email: [email protected]